Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 10, 2012, Pages 3623-3627

  Malley, Richard ^a   Anderson, Porter W ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

B cell immunity; T cell immunity

Indexed keywords

INTERLEUKIN 17; PNEUMOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL CLEARANCE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMORAL IMMUNITY; MOUSE; NASOPHARYNX; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SEROTYPE;

ANIMALS; ANTIGENS, SURFACE; B-LYMPHOCYTES; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERLEUKIN-17; MICE; MUCOUS MEMBRANE; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; T-LYMPHOCYTES;

BACTERIA (MICROORGANISMS); MUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84857951109     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1121383109     Document Type: Article

References (75)

1. O'Brien KL, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 374:893-902.
2. Tomasz A (1967) Choline in the cell wall of a bacterium: Novel type of polymer-linked choline in Pneumococcus. Science 157:694-697.
3. Tomasz A (1981) Surface components of Streptococcus pneumoniae. Rev Infect Dis 3: 190-211.
4. Fischer H, Tomasz A (1985) Peptidoglycan cross-linking and teichoic acid attachment in Streptococcus pneumoniae. J Bacteriol 163:46-54. (Pubitemid 15011715)
5. Tuomanen E, Tomasz A, Hengstler B, Zak O (1985) The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis 151:535-540. (Pubitemid 15103808)
6. Tuomanen E, Liu H, Hengstler B, Zak O, Tomasz A (1985) The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis 151:859-868. (Pubitemid 15094604)
7. Tuomanen E, Hengstler B, Zak O, Tomasz A (1986) Induction of meningeal inflammation by diverse bacterial cell walls. Eur J Clin Microbiol 5:682-684. (Pubitemid 17213580)
8. Tomasz A, Saukkonen K (1989) The nature of cell wall-derived inflammatory components of pneumococci. Pediatr Infect Dis J 8:902-903. (Pubitemid 20018858)
9. Makela PH, Butler JC (2008) History of pneumococcal immunization. Pneumococcal Vaccines: The Impact of Conjugate Vaccine, eds Siber GR, Klugman KP, Makela PH (ASM Press, Washington, DC), pp 19-29.
10. Chien YW, Klugman KP, Morens DM (2010) Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis 202:1639-1648.
11. Heidelberger M, Avery OT (1923) The soluble specific substance of pneumococcus. J Exp Med 38:73-79.
12. Avery OT, Macleod CM, McCarty M (1944) Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 79: 137-158.
13. Macleod CM, Hodges RG, Heidelberger M, Bernhard WG (1945) Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 82:445-465.
14. Austrian R, Gold J (1964) Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60:759-776.
15. Robbins JB, et al. (1983) Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148:1136-1159. (Pubitemid 14206325)
16. Douglas RM, Paton JC, Duncan SJ, Hansman DJ (1983) Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 148: 131-137. (Pubitemid 13039322)
17. Koskela M, Leinonen M, Häivä VM, Timonen M, Mäkelä PH (1986) First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 5:45-50. (Pubitemid 16155258)
18. Sell SH, Wright PF, Vaughn WK, Thompson J, Schiffman G (1981) Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis 3(Suppl):S97-S107.
19. Avery OT, Goebel WF (1929) Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 50:533-550.
20. Goebel WF, Avery OT (1929) Chemo-immunological studies on conjugated carbohydrate-proteins: I. The synthesis of p-aminophenol beta-glucoside, p-aminophenol beta-galactoside, and their coupling with serum globulin. J Exp Med 50:521-531.
21. Schneerson R, Barrera O, Sutton A, Robbins JB (1980) Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 152:361-376. (Pubitemid 10037059)
22. Anderson P (1983) Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 39:233-238.
23. Black SB, et al. (1991) Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis J 10:97-104.
24. Black S, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19:187-195. (Pubitemid 30167436)
25. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378:1962-1973.
26. Levy C, et al. (2011) PneumococcaL meningitis in french children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 30:168-170.
27. Croucher NJ, et al. (2011) Rapid pneumococcal evolution in response to clinical interventions. Science 331:430-434.
28. Janeway CA, Travers P, Walport M, Shlomchik MJ (2005) Immunobiology (Garland, New York), 6th Ed, p 462.
29. Austrian R (1986) Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 18(Suppl A):35-45.
30. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI (1995) Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377:435-438.
31. Weiser JN (2010) The pneumococcus: Why a commensal misbehaves. J Mol Med (Berl) 88:97-102.
32. Weiser JN, Austrian R, Sreenivasan PK, Masure HR (1994) Phase variation in pneumococcal opacity: Relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 62:2582-2589. (Pubitemid 24157093)
33. Weiser JN, Markiewicz Z, Tuomanen EI, Wani JH (1996) Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun 64: 2240-2245. (Pubitemid 26165685)
34. Briles EB, Tomasz A (1973) Pneumococcal Forssman antigen. A choline-containing lipoteichoic acid. J Biol Chem 248:6394-6397.
35. Briles DE, Yother J, McDaniel LS (1988) Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis 10(Suppl 2):S372-S374.
36. Paton JC, Lock RA, Hansman DJ (1983) Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 40: 548-552. (Pubitemid 13133264)
37. Moffitt KL, Malley R (2011) Next generation pneumococcal vaccines. Curr Opin Immunol 23:407-413.
38. Briles DE, et al. (2000) Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68:796-800. (Pubitemid 30056538)
39. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, Paton JC (2000) Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68: 3028-3033. (Pubitemid 30253892)
40. Nabors GS, et al. (2000) Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18:1743-1754. (Pubitemid 30122836)
41. Briles DE, et al. (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182: 1694-1701.
42. Nagy E (2010) IC47, a novel protein-based pneumococcal vaccine: From bench to the clinic. Proceedings of the Seventh International Symposium on Pneumococci and Pneumococcal Diseases. Available at http://www.multiwebcast.com/ isppd/2010/7th/ 4572/eszter.nagy.ic47.a.novel.protein-based.pneumococcal. vaccine.from.bench.to.the. html. Accessed January 19, 2012.
43. Nayak AR, et al. (1998) A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun 66:3744-3751. (Pubitemid 28347832)
44. Xin W, Li Y, Mo H, Roland KL, Curtiss R 3rd (2009) PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 77:4518-4528.
45. Lipsitch M, et al. (2007) Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J Infect Dis 196:1221-1227. (Pubitemid 47580277)
46. Hanage WP, et al. (2007) Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 195:347-352. (Pubitemid 46146111)
47. Moffitt KL, et al. (2011) T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 9:158-165.
48. Haneberg B, Herland Berstad AK, Holst J (2001) Bacteria-derived particles as adjuvants for non-replicating nasal vaccines. Adv Drug Deliv Rev 51:143-147. (Pubitemid 32763078)
49. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440:808-812.
50. Brodsky IE, Medzhitov R (2009) Targeting of immune signalling networks by bacterial pathogens. Nat Cell Biol 11:521-526.
51. Malley R, et al. (2001) Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 69:4870-4873. (Pubitemid 32674467)
52. Malley R, et al. (2004) Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 72:4290-4292. (Pubitemid 38821947)
53. Malley R, et al. (2005) CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102:4848-4853. (Pubitemid 40471542)
54. Kadioglu A, Coward W, Colston MJ, Hewitt CR, Andrew PW (2004) CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 72:2689-2697. (Pubitemid 38542395)
55. McCool TL, Weiser JN (2004) Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun 72:5807-5813. (Pubitemid 39303692)
56. Lipsitch M, et al. (2005) Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med 2:e15.
57. Aujla SJ, Dubin PJ, Kolls JK (2007) Th17 cells and mucosal host defense. Semin Immunol 19:377-382. (Pubitemid 351274047)
58. Kolls JK, Lindén A (2004) Interleukin-17 family members and inflammation. Immunity 21:467-476. (Pubitemid 39370503)
59. Ye P, et al. (2001) Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 25:335-340. (Pubitemid 32918915)
60. Khader SA, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8:369-377. (Pubitemid 46745412)
61. Brereton CF, et al. (2011) Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol 186:5896-5906.
62. Lu YJ, et al. (2008) Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 4:e1000159.
63. Zhang Z, Clarke TB, Weiser JN (2009) Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119:1899-1909.
64. McAleer JP, Kolls JK (2011) Mechanisms controlling Th17 cytokine expression and host defense. J Leukoc Biol 90:263-270.
65. Lu YJ, et al. (2010) Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 17:1005-1012.
66. Mutsch M, et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350:896-903. (Pubitemid 38252537)
67. Lu YJ, et al. (2010) GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 28:7468-7475.
68. Moffitt KL, Yadav P, Weinberger D, Anderson PW, Malley R (2012) Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine, in press.
69. Cobb BA, Wang Q, Tzianabos AO, Kasper DL (2004) Polysaccharide processing and presentation by the MHCII pathway. Cell 117:677-687. (Pubitemid 38692532)
70. Kalka-Moll WM, et al. (2002) Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol 169:6149-6153. (Pubitemid 36903459)
71. Tzianabos AO, et al. (2000) T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem 275:6733-6740. (Pubitemid 30146209)
72. Malley R, et al. (2006) Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 74:2187-2195.
73. Lu YJ, Skovsted IC, Thompson CM, Anderson PW, Malley R (2009) Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide. Microb Pathog 47:177-182.
74. Malley R, et al. (2003) Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 100:1966-1971. (Pubitemid 36254557)
75. Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R (2009) Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 77:2076-2083.